ECSP055604A - Métodos de administrar y aumentar la absorción de agentes farmacéuticos - Google Patents

Métodos de administrar y aumentar la absorción de agentes farmacéuticos

Info

Publication number
ECSP055604A
ECSP055604A EC2005005604A ECSP055604A ECSP055604A EC SP055604 A ECSP055604 A EC SP055604A EC 2005005604 A EC2005005604 A EC 2005005604A EC SP055604 A ECSP055604 A EC SP055604A EC SP055604 A ECSP055604 A EC SP055604A
Authority
EC
Ecuador
Prior art keywords
methods
managing
absorption
increasing
pharmaceutical agents
Prior art date
Application number
EC2005005604A
Other languages
English (en)
Inventor
Pankaj Modi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of ECSP055604A publication Critical patent/ECSP055604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Abstract

Las composiciones farmacéuticas comprenden un agente farmacéutico macromolecular en forma de micelas mixtas. Las micelas mixtas estan formadas de un alquilosulfato de metales alcalinos y por lo menos tres diferentes compuestos que forman micelas como se describe en la especificación. El tamaño aproximado de la micela es entre 1 y 10 nanometros (nm). Los métodos para administrar las composiciones se revelan también. Un método preferido para administrar la presente composición es a través de la boca, la cuál fue demostrado para lograr niveles plasmáticos de un agente farmacéutico en acerca treinta minutos.
EC2005005604A 2002-08-16 2005-02-16 Métodos de administrar y aumentar la absorción de agentes farmacéuticos ECSP055604A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/222,240 US7087215B2 (en) 1998-12-21 2002-08-16 Methods of administering and enhancing absorption of pharmaceutical agents

Publications (1)

Publication Number Publication Date
ECSP055604A true ECSP055604A (es) 2005-04-18

Family

ID=31886615

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005604A ECSP055604A (es) 2002-08-16 2005-02-16 Métodos de administrar y aumentar la absorción de agentes farmacéuticos

Country Status (8)

Country Link
US (1) US7087215B2 (es)
EP (1) EP1556003A2 (es)
JP (1) JP2006501220A (es)
BR (1) BR0313494A (es)
CA (1) CA2494132C (es)
EC (1) ECSP055604A (es)
MX (1) MXPA05001887A (es)
WO (1) WO2004016243A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1431919A (zh) * 2000-04-03 2003-07-23 巴特勒记忆研究所 装置和制剂
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
AU2005235369B2 (en) * 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
AP2008004447A0 (en) * 2005-11-30 2008-04-30 Generex Pharm Inc Orally absorbed pharmaceutical formulation and method of administration
SI1976521T1 (sl) * 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
US20080085331A1 (en) * 2006-10-06 2008-04-10 Gluskin Anna E Composition and method for raising blood glucose level
GB0621707D0 (en) * 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
EP2180844B1 (en) 2007-08-02 2018-02-21 Insys Development Company, Inc. Sublingual fentanyl spray
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
EP2575761A1 (en) * 2010-05-28 2013-04-10 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
US8580853B2 (en) 2011-06-13 2013-11-12 Howard PHYKITT Analgesic composition and method of making the same

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53107408A (en) * 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
EP0200383A3 (en) 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
WO1991015241A1 (en) * 1990-03-30 1991-10-17 Yasunori Morimoto Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
IT1255449B (it) * 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
US5981591A (en) * 1992-12-04 1999-11-09 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use
DE69413955T2 (de) * 1993-03-17 1999-04-01 Minnesota Mining & Mfg Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel
WO1994021228A1 (en) * 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
HUT75676A (en) * 1994-03-07 1997-05-28 Inhale Therapeutic Syst Methods and compositions for pulmonary delivery of insulin
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP2740153B2 (ja) * 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー 混合ミセル
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
CN1195981A (zh) 1995-06-07 1998-10-14 联合药品公司 药物输送用的反相碳氟化合物乳液组合物
PT910339E (pt) * 1996-04-12 2005-05-31 Novadel Pharma Inc Aerossol polar bucal
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
IL127956A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US6090407A (en) * 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
IL122084A (en) 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6294153B1 (en) * 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
MXPA01009466A (es) 1999-03-19 2002-05-14 Generex Pharm Inc Preparacion farmaceutica solubilizada en propelente de aerosol.
CA2375914A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6225343B1 (en) * 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route

Also Published As

Publication number Publication date
MXPA05001887A (es) 2005-06-17
US20030157029A1 (en) 2003-08-21
WO2004016243A3 (en) 2004-05-21
JP2006501220A (ja) 2006-01-12
WO2004016243A2 (en) 2004-02-26
BR0313494A (pt) 2005-07-05
CA2494132C (en) 2015-01-20
US7087215B2 (en) 2006-08-08
CA2494132A1 (en) 2004-02-26
EP1556003A2 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
ECSP055604A (es) Métodos de administrar y aumentar la absorción de agentes farmacéuticos
BR0001515A (pt) Composições de espuma estáveis
AR041911A1 (es) Proceso para la preparacion de nanocompuestos de poliolefina
WO2004087052A3 (en) Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
DK1261320T3 (da) Micellare farmaceutiske sammesætninger til bukkal og pulmonal anvendelse
MXPA02011436A (es) Composiciones farmaceuticas micelares para aplicacion bucal y pulmonar.
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
DK1819227T3 (da) Farmaceutisk formulering af decitabin
PE20001032A1 (es) Composiciones y metodos para tratar enfermedades pulmonares
BRPI0506977A (pt) composto de tetrahidrocarbolina como agentes anticáncer
AR069438A1 (es) Formulaciones en solucion que contienen clorhidrato de moxifloxacina y fosfato de dexametasona para uso oftalmico u otico por via topica
BRPI0509505A (pt) método e kit útil para branqueamento de uma superfìcie dental
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
ITRM20080472A1 (it) Uso di enhancer eventualmente con riboflavina, nonche' relative composizioni oftalmiche per cross-linking corneale del cheratocono o di altre patologie ectasiche corneali
ECSP12006512A (es) Formulacion y método de aripiprazol inyectable esteril de liberacion controlada
BR9813826A (pt) Potencial de uso abusivo de administração oral de opióide analgésico
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
ECSP077262A (es) Composicion antihistaminica
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
BRPI0517451A (pt) composição oftámilca, e, métodos de tratar conjutivite alérgica e doença de olho seco
DE69426570D1 (de) Mizelleförmige feinteilige pharmazeutische zusammensetzungen
AR072333A1 (es) Composiciones inyectables a base de taxoides
GT201000138A (es) " mezcla herbicida "
BR0316735A (pt) Agentes dispersantes de polìmero de olefina oxidado, irradiado